A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells

(2010) E. Martinez-Garcia et al.   BLOOD

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

(2010) Kihyun Kim et al.   BRITISH JOURNAL OF HAEMATOLOGY

Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non-Small Cell Lung Cancer Cell Lines

(2010) E. B. Garon et al.   MOLECULAR CANCER THERAPEUTICS

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

(2008) Y. Dai et al.   BLOOD

Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways

(2008) P. Lunghi et al.   BLOOD

Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer

(2008) C. A. Pratilas et al.   CANCER RESEARCH

BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins

(2008) B. B. Friday et al.   CANCER RESEARCH

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE

Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs

(2007) William Bensinger   JOURNAL OF CLINICAL ONCOLOGY